Nanobiotix S.A. (NBTX) News
Follow Nanobiotix S.A. (NBTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nanobiotix Reports 41.7% Response Rate for JNJ-1900 Melanoma Study
Nanobiotix reported a 41.7% response rate for JNJ-1900 in a Phase I study of anti-PD-1-resistant melanoma.
EQUITY | Oct 26, 2026, 08:38 AM UTC
L
NBTX - Voting Rights and Shares Capital of the Company
NBTX - Voting Rights and Shares Capital of the Company
EQUITY | Sep 22, 2026, 08:15 PM UTC
L
NBTX - NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
NBTX - NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
NEWS | Sep 14, 2026, 06:00 AM UTC
L
NBTX - NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NBTX - NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 09, 2026, 08:15 PM UTC
L
NBTX - Voting Rights and Shares Capital of the Company
NBTX - Voting Rights and Shares Capital of the Company
EQUITY | Aug 25, 2026, 08:15 PM UTC